PEPG PepGen
- 14.200
- -0.290-2.00%
- 14.200
- 0.0000.00%
PepGen News
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
Insiders Buying GameStop And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (Nasdaq: PEPG) today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.
Stifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
Earnings Call Summary | PepGen(PEPG.US) Q4 2023 Earnings Conference
The following is a summary of the PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript:Financial Performance:PepGen finished 2023 with $110.4 million in cash and cash equivalents, a significant decrea
Berkshire Hills Bancorp, Inc. Declares $0.18 Dividend
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (
PepGen Reported March 6 Q4 2023 GAAP EPS $(0.810) Beats $(1.010) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.810) per share which beat the analyst consensus estimate of $(1.010) by 19.8 percent.
Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), PepGen Inc. (PEPG)
PepGen Is Maintained at Outperform by Wedbush
PepGen Is Maintained at Outperform by Wedbush
Wedbush Maintains Outperform on PepGen, Lowers Price Target to $20
Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $21 to $20.
PepGen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 29.79% Wedbush $21 → $20 Maintains Outperform 01/30/2024 36.28% Wedbush → $21 Reiterates Outper
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), ITeos Therapeutics (ITOS) and Rezolute (RZLT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
PepGen 4Q Loss $19.5M >PEPG
PepGen 4Q Loss $19.5M >PEPG
PepGen Sees Operating Cash Runway Into 2026 >PEPG
PepGen Sees Operating Cash Runway Into 2026 >PEPG
Press Release: PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DM
Analysis
Price Target
No Data
